ZBTB7

In one line: A single transcription factor — a gene whose only job is to switch other genes off — that was nicknamed "Pokemon," renamed under legal pressure, and turns out to drive cancer, restrain it, and silence the fetal hemoglobin medicine is now racing to switch back on.

---

The gene

Officially it's ZBTB7A ("zinc finger and BTB domain containing 7A"), on the short arm of chromosome 19 (19p13.3). But it answers to several names: LRF in the blood literature, FBI-1 in its first cloning, and — most famously — Pokemon. In 2005 Pier Paolo Pandolfi's lab at Memorial Sloan-Kettering characterized it as a proto-oncogene and gave it a cheeky acronym: POK erythroid myeloid ontogenic factor. "POK" itself stands for the protein's two business ends — a POZ/BTB domain and a Krüppel zinc-finger.

The function is the whole story. ZBTB7A is a transcriptional repressor: one end (the zinc fingers) clamps a specific stretch of DNA, the other (the BTB/POZ domain) recruits the cell's silencing machinery, and the target gene goes quiet. A repressor that picks which genes stay dark is, in effect, helping decide what a cell becomes.

The name

When the 2005 paper produced headlines like "Pokemon causes cancer," The Pokémon Company objected — they did not want a children's franchise associated with a cancer gene. It was a threat of legal action, not a filed lawsuit (and the Pokémon Company, not Nintendo itself). Memorial Sloan-Kettering voluntarily dropped the nickname; the gene nomenclature committee standardized ZBTB7A.

The mechanism

As "Pokemon," the protein represses ARF (p14ARF, from the CDKN2A locus). ARF normally inhibits MDM2, which otherwise degrades p53 — the cell's master guardian. So when ZBTB7A is dialed up, ARF goes quiet, p53 weakens, and a cell that should self-destruct keeps dividing. The 2005 paper showed cells lacking the gene were "completely refractory" to transformation by other oncogenes — a genuine proto-oncogene.

But the same repressor has a second face. In other tissues it silences genes that fuel growth — and there it behaves as a tumor suppressor: recurrently mutated in t(8;21) acute myeloid leukemia, and a repressor of glycolysis whose locus is deleted in many solid tumors. Same protein, opposite role — it depends entirely on which genes it is holding shut.

The stakes, and the frontier

One of those silenced genes ties this story to another. Under the name LRF, ZBTB7A is one of the switches that turns off fetal hemoglobin after birth — binding the γ-globin promoters independently of BCL11A, the other major repressor. Reactivating fetal hemoglobin is the strategy behind today's sickle-cell and β-thalassemia therapies. The approved CRISPR therapy Casgevy targets BCL11A, not LRF — but LRF/ZBTB7A is an active, research-stage target in its own right (early degrader molecules can raise fetal hemoglobin sharply in cultured cells). The cancer gene a cartoon company disowned may yet be a lever for curing an inherited blood disease.

Sources

Full claim-by-claim evidence is in references.md. Primary anchors:

• Maeda et al., Nature 433:278 (2005) — "Pokemon," ARF repression, proto-oncogene.
• Simonite, Nature 438:897 (2005) — the name dispute / rename.
• Maeda et al., Science 316:860 (2007) — B-vs-T lineage fate.
• Hartmann et al., Nat Commun 7:11733 (2016) — ZBTB7A as a tumor suppressor in t(8;21) AML.
• Liu et al., Genes Dev 28:1917 (2014) — repression of glycolysis (tumor-suppressor role).
• Masuda et al., Science 351:285 (2016) — LRF represses fetal hemoglobin independently of BCL11A.

Accuracy note: the episode is careful on three commonly-confused points — (1) it was a legal threat from the Pokémon Company, not a Nintendo lawsuit; (2) ZBTB7A is context-dependent (oncogene in lymphoma, tumor suppressor in t(8;21) AML), so "required for transformation" is stated as the lymphoid/MEF result; (3) the approved therapy Casgevy edits BCL11A, not LRF/ZBTB7A — LRF is presented as a parallel, research-stage target.